Skip to main content
SpringerLink
Log in

A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocho-line) in non-small cell bronchogenic carcinoma, using a schedule of continuous infusion for 5 days and a dose of 300 mg/m2/day. Toxicities were gastrointestinal (nausea, vomiting, diarrhea), fatigue and liver function abnormalities. These were severe and resulted in the removal of some patients from study. No consistent pattern of bone marrow suppression was seen. No tumor regressions occurred in 14 evaluable patients including 5 with no prior therapy. We conclude that ilmofosine is inactive in this tumor at this dose and schedule.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hanauske A, Degen D, Marshall MH, Hilsenbeck SG, McPhillips JJ, Von Hoff DD: Preclinical activity of ilmofosine against human tumor colony forming units in vitro. Anti-Cancer Drugs 3:43–46, 1992

    Google Scholar 

  2. Herrmann DB, Pahlke W, Opitz H-G, Bicker U: In vivo antitumor activity of ilmofosine. Cancer Treat Rev 17:247–252, 1990

    Google Scholar 

  3. Herman DBJ, Opitz H-G, Munder PG: Antitumor activity of ilmofosine (BM41440) in the 3 Lewis-lung carcinoma model. Lipids 26:1431–1436, 1991

    Google Scholar 

  4. Rodriguez G, Havlin K, Burris H, Wall J, Schaffer D, Smith L, Kalter S, Brown T, Cagnola J, Weiss G, Kneuper Hall R, Von Hoff D: Phase I clinical trial of ilmofosine, a novel antitumor agent. Proc Am Soc Clin Oncol (Abstract) 10:114, 1991

    Google Scholar 

  5. Rodriguez G, O'Dwyer PJ, Derry C, McAleer C, McPhillips J, Ozols RF: Phase I pharmacokinetic trial of weekly ilmofosine (BM41440). Proc Am Soc Clin Oncol (Abstract) 12:157, 1993

    Google Scholar 

  6. Koeller J, Rodriguez G, Smith L, Eckardt J, Shaffer D, Weiss G, Higashi L, McPhillips J, Von Hoff D: Phase I study of ilmofosine given as a 120 hour continuous infusion in patients with solid tumors. Proc Am Soc Clin Oncol 12:155, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laurel Highlands Cancer Program, Conemaugh's Memorial Medical Center, Lee Hospital and Windber Hospital, 15905, Johnstown, PA, USA

    Paul V. Woolley, Carolyn J. Schultz, Kenneth W. Rowe Jr. & Mary Lee Dadey

  2. Cancer Therapy and Research Center, 782229-3272, San Antonio, TX, USA

    Gladys I. Rodriguez & Daniel D. Von Hoff

  3. Division of Hematology and Oncology, Ohio State University Medical Center, 43210-1236, Columbus, OH, USA

    Richard A. Gams

  4. Therapeutic Division, Boehringer-Mannheim Corporation, 20878, Gaithersburg, MD, USA

    Joseph J. McPhillips

Authors
  1. Paul V. Woolley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carolyn J. Schultz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gladys I. Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard A. Gams
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenneth W. Rowe Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mary Lee Dadey
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daniel D. Von Hoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Joseph J. McPhillips
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Woolley, P.V., Schultz, C.J., Rodriguez, G.I. et al. A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma. Invest New Drugs 14, 219–222 (1996). https://doi.org/10.1007/BF00210794

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00210794

Key words

Search

Navigation